PPARG and fatty liver disease: Many studies showed that rosiglitazone and pioglitazone significantly improved hepatic steatosis [20, 21], and this effect of these drugs is largely explained by the secondary effect of improving the insulin sensitivity of adipose tissue, where PPARγ level is mainly high [7, 8].